Toll Like Receptor 3 (CD283 or TLR3) - Drugs in Development, 2021

March 2021 | 91 pages | ID: TADAF7ABF688EN
Global Markets Direct

Abstracts

Toll Like Receptor 3 (CD283 or TLR3) - Drugs in Development, 2021

SUMMARY

Toll Like Receptor 3 (CD283 or TLR3) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Toll Like Receptor 3 - Drugs in Development, 2021, outlays comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Toll Like Receptor 3 (CD283 or TLR3) - Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. It acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response. The molecules developed by companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Report covers products from therapy areas Oncology, Infectious Disease, Gastrointestinal, Immunology, Central Nervous System and Respiratory which include indications Coronavirus Disease 2019 (COVID-19), Melanoma, Bladder Cancer, Breast Cancer, Epithelial Ovarian Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Metastatic Colorectal Cancer, Peritoneal Cancer, Severe Acute Respiratory Syndrome (SARS), Acute Inflammation, Chronic Fatigue Syndrome (Myalgic Encephalomyelitis), Chronic Inflammation, Colon Cancer, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Cytomegalovirus (HHV-5) Infections, Ebolavirus Infections (Ebola Hemorrhagic Fever), Fallopian Tube Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatitis B, Hepatocellular Carcinoma, Herpes Labialis (Oral Herpes), Inflammation, Influenza A Virus, H3N2 Subtype Infections, Influenza A Virus, H5N1 Subtype Infections, Influenza A Virus, H7N9 Subtype Infections, Kidney Cancer (Renal Cell Cancer), Malignant Pleural Mesothelioma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Melanoma, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pandemic Influenza, Prostate Cancer, Pulmonary Inflammation, Renal Cell Carcinoma, Rhinovirus Infections, Sarcomas, Triple-Negative Breast Cancer (TNBC), Ulcerative Colitis, Unspecified Influenza Virus Infections, West Nile Virus Infections and Zika Virus Infections.

Furthermore, this report also reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 3 (CD283 or TLR3)
• The report reviews Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics and enlists all their major and minor projects
• The report assesses Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Toll Like Receptor 3 (CD283 or TLR3)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Toll Like Receptor 3 (CD283 or TLR3) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Toll Like Receptor 3 (CD283 or TLR3) - Overview
Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 3 (CD283 or TLR3) - Companies Involved in Therapeutics Development
13therapeutics Inc
AIM ImmunoTech Inc
Glysantis Inc
HDT Bio Corp
Highlight Therapeutics SL
Oncovir Inc
PrEP Biopharm Ltd
Provention Bio Inc
Tollys SAS
Yisheng Biopharma Co Ltd
Toll Like Receptor 3 (CD283 or TLR3) - Drug Profiles
Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BO-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLY-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Agonize TLR3 for Head and Neck Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Poly-ICLC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PrEP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRV-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rintatolimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize TLR-3 for Gastrointestinal Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TL-532 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YSHBV-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Toll Like Receptor 3 (CD283 or TLR3) - Dormant Products
Toll Like Receptor 3 (CD283 or TLR3) - Discontinued Products
Toll Like Receptor 3 (CD283 or TLR3) - Product Development Milestones
Featured News & Press Releases
Mar 22, 2021: AIM ImmunoTech announces addition of single-agent Ampligen arm to Cancer Center’s ongoing study in cancer patients with COVID-19
Mar 09, 2021: AIM ImmunoTech initiates dosing in intranasal Covid-19 drug study
Mar 02, 2021: Highlight & Pivotal start Phase IIa melanoma trial
Feb 24, 2021: AIM ImmunoTech’s subsidiary receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to treat pancreatic cancer
Feb 17, 2021: AIM ImmunoTech to commence study of intranasal Covid-19 therapy
Feb 17, 2021: AIM ImmunoTech to commence study of intranasal Covid-19 therapy
Feb 10, 2021: AIM ImmunoTech announces the expansion of its pancreatic cancer program to include new patients in the Netherlands
Jan 29, 2021: AIM ImmunoTech enters into agreement for proposed intranasal safety study of ampligen
Jan 07, 2021: AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection
Dec 24, 2020: AIM ImmunoTech announces availability of the ME/CFS clinical trial of its drug Ampligen for enrollment to COVID-19 ‘Long Haulers’
Dec 23, 2020: Open Orphan: Successful completion of PrEP Biopharm Toxicology study for respiratory 'viral mimic'
Dec 21, 2020: AIM ImmunoTech's drug Ampligen awarded FDA’s Orphan Drug Designation status for the treatment of pancreatic cancer
Dec 16, 2020: PrEP Biopharm announces successful completion of PrEP-001 toxicology study enabling phase 2b field study of PrEP-001 against all respiratory viruses
Nov 25, 2020: AIM announces milestone in covid-19 treatment and prevention efforts with first patient dosed in study evaluating Ampligen as part of combination treatment for patients with cancer and covid-19
Nov 02, 2020: AIM ImmunoTech announces PLOS ONE’s publication of new data analyses showing importance of disease duration on Ampligen’s positive role in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by 13therapeutics Inc, 2021
Pipeline by AIM ImmunoTech Inc, 2021
Pipeline by Glysantis Inc, 2021
Pipeline by HDT Bio Corp, 2021
Pipeline by Highlight Therapeutics SL, 2021
Pipeline by Oncovir Inc, 2021
Pipeline by PrEP Biopharm Ltd, 2021
Pipeline by Provention Bio Inc, 2021
Pipeline by Tollys SAS, 2021
Pipeline by Yisheng Biopharma Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021